Vanguard Group Inc. Grows Stock Position in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)

Vanguard Group Inc. lifted its holdings in shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) by 1.5% during the fourth quarter, according to its most recent disclosure with the SEC. The fund owned 5,631,321 shares of the biopharmaceutical company's stock after acquiring an additional 85,339 shares during the period. Vanguard Group Inc. owned approximately 9.87% of Agios Pharmaceuticals worth $185,045,000 at the end of the most recent quarter.

Other hedge funds have also recently modified their holdings of the company. Venturi Wealth Management LLC purchased a new stake in Agios Pharmaceuticals during the 4th quarter worth approximately $33,000. Wingate Wealth Advisors Inc. acquired a new stake in shares of Agios Pharmaceuticals during the fourth quarter worth $53,000. KBC Group NV increased its position in shares of Agios Pharmaceuticals by 30.5% in the 4th quarter. KBC Group NV now owns 2,615 shares of the biopharmaceutical company's stock valued at $86,000 after acquiring an additional 611 shares during the period. AlphaQuest LLC increased its position in shares of Agios Pharmaceuticals by 106.2% in the 4th quarter. AlphaQuest LLC now owns 4,540 shares of the biopharmaceutical company's stock valued at $149,000 after acquiring an additional 2,338 shares during the period. Finally, AlphaCentric Advisors LLC purchased a new position in Agios Pharmaceuticals in the 4th quarter worth $202,000.

Insiders Place Their Bets

In other Agios Pharmaceuticals news, Director Jacqualyn A. Fouse sold 7,497 shares of the company's stock in a transaction on Thursday, April 10th. The shares were sold at an average price of $25.90, for a total transaction of $194,172.30. Following the completion of the transaction, the director now directly owns 149,220 shares in the company, valued at approximately $3,864,798. This represents a 4.78 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. 4.93% of the stock is currently owned by company insiders.

Agios Pharmaceuticals Stock Performance

NASDAQ AGIO traded up $1.39 during mid-day trading on Friday, reaching $26.70. 592,295 shares of the stock were exchanged, compared to its average volume of 711,070. The company has a market capitalization of $1.53 billion, a P/E ratio of 2.35 and a beta of 0.83. The business's 50 day moving average is $31.39 and its 200-day moving average is $39.24. Agios Pharmaceuticals, Inc. has a 1 year low of $23.42 and a 1 year high of $62.58.

Agios Pharmaceuticals (NASDAQ:AGIO - Get Free Report) last posted its earnings results on Thursday, February 20th. The biopharmaceutical company reported ($1.74) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.69) by ($0.05). Agios Pharmaceuticals had a negative return on equity of 2.51% and a net margin of 1,845.92%. Equities analysts predict that Agios Pharmaceuticals, Inc. will post -6.85 earnings per share for the current fiscal year.

Analysts Set New Price Targets

AGIO has been the topic of a number of research reports. StockNews.com lowered Agios Pharmaceuticals from a "hold" rating to a "sell" rating in a report on Friday, February 14th. Cantor Fitzgerald reissued an "overweight" rating on shares of Agios Pharmaceuticals in a research report on Wednesday, December 18th. Finally, HC Wainwright started coverage on shares of Agios Pharmaceuticals in a research note on Monday, February 24th. They set a "buy" rating and a $58.00 price objective for the company. One analyst has rated the stock with a sell rating, four have given a hold rating and five have issued a buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of "Hold" and an average target price of $56.57.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.